Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

The effects of Finasteride, a drug used to treat hair loss, prostate problems and other conditions. The post by iaskedadoctor describes the conversations they had with a Urologist about the effects of the drug on DHT levels throughout the body, how lower doses are beneficial in reducing side effects, how erectile dysfunction can be psychological as well as physiological, how morning erections are not necessarily important, and how persistent side effects appear to be rare. People also shared their experiences with taking Finasteride for hair loss, including potential side effects such as reduced ejaculate force and development of man boobs.

Finasteride can cause gynecomastia, which may be reversible by stopping the drug and using selective estrogen receptor modulators (SERMs) like tamoxifen. Lifestyle changes such as weight loss and avoiding alcohol can also help, but surgery may be needed if the condition persists.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

The conversation discusses whether long-term use of finasteride (Fin) is harmful to the liver, with various opinions on side effects and comparisons to other substances. Specific treatments mentioned include finasteride, minoxidil (Min), and RU58841 (RU).

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

Adding RU58841 to Dutasteride treatment helped reduce hair shedding significantly for several users. Some reported no change with RU58841, while others experienced a dramatic decrease in shedding and increased hair density.

The post is about a user's progress with using finasteride, minoxidil, and dermarolling for hair loss. The conversation includes comments about different treatments and methods used.

A user with low testosterone and mild gyno is considering finasteride for hair loss. Others suggest consulting an endocrinologist first and share experiences of finasteride not worsening gyno.

A 19-year-old experienced worsening hair loss after 4 months on finasteride, despite initial improvement with minoxidil. The consensus is to continue treatment for at least a year, as shedding is common and often temporary.

The user saw no improvement in hair loss after using Finasteride for a year and Dutasteride for six months. They also experienced scalp inflammation and tried various treatments like Ketoconazole and Salicylic Acid without success.

A user experienced dry, brittle hair after starting dutasteride and considered switching back to finasteride. Another user advised that the dryness is temporary and shared positive results with dutasteride and oral minoxidil after several months.

The conversation discusses skepticism around claims that dutasteride worsens hair loss, with some users suggesting misinformation or panic during shedding as reasons for such claims. One user shared their negative experience with dutasteride, including increased sebum production and hair loss, and is now considering a higher dose of oral minoxidil after stopping dutasteride.

The conversation discusses using a low dose of topical finasteride to achieve hair benefits with minimal systemic exposure. Users share experiences and opinions on dosing, systemic buildup, and side effects of both topical and oral finasteride.

Hair loss, genetics and possible treatments such as minoxidil, dermarolling and finasteride.

Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.

The conversation discusses using oral minoxidil for advanced hair loss and whether it's safe to consume energy drinks while on this medication. It also questions the benefits of combining microneedling and tretinoin with oral minoxidil treatment.

A 20-year-old user experienced worsening hair loss despite using various treatments including topical and oral minoxidil, finasteride, and dutasteride. Other users suggested additional treatments like JAK inhibitors, RU58841, and lifestyle changes, but the user remains skeptical and frustrated.

The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

A user shared their 6-month results using minoxidil 5% and finasteride 1mg daily, but still experiences significant shedding. Suggestions included seeing a dermatologist, using apple cider vinegar for dandruff, and considering oral minoxidil and dutasteride.

People over 35 have seen success with finasteride, minoxidil, and dutasteride for hair loss. Results vary, with some noticing improvements in hair volume and hairline, while others emphasize patience and managing expectations.

The conversation discusses hair loss treatments, with users mentioning dutasteride (Dut) as effective and wishing for more accessible dosages. They also debate the components of the "big 3" treatments, which now include Dut, RU58841, and oral minoxidil, with finasteride and minoxidil being consistently mentioned.

The user visited three dermatologists for hair loss treatment and was disappointed with their lack of thorough examination and discussion. Treatments prescribed included minoxidil, finasteride, multivitamins, ketoconazole shampoo, vitamin D3, and biotin, but the user was dissatisfied with the approach and lack of consideration for newer treatments.

The user started using Hims Finasteride and Minoxidil topical in July 2023, added daily microneedling in November, and switched to chewable Finasteride and Minoxidil in January with increased microneedling frequency. They observed hair regrowth, suggesting diffuse thinning may be easier to treat.

The conversation is about a finding that finasteride does not significantly increase the risk of sexual dysfunction, with users sharing mixed personal experiences regarding side effects.

The user started taking 2.5mg minoxidil tablets daily and reduced their finasteride dose to 0.5mg due to side effects. They are considering a hair transplant but are unsure if they should proceed now or wait after seeing the effects of the reduced finasteride dosage.

The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.